Xifaxan
My Prescription
Payment
Select pharmacy
$3,078.87
Print or send this coupon to your phone
CVSPowered byAbout Xifaxan
Drug Details
Rifaximin, commercially known as Xifaxan, is an antibiotic classified under rifamycins. It is specifically designed for treating travelers' diarrhea caused by the E. coli bacteria in individuals aged 12 and older. Additionally, it is effective in managing irritable bowel syndrome with diarrhea (IBS-D) and in preventing hepatic encephalopathy, a brain condition related to liver disease, in adults. The medication works by inhibiting the synthesis of essential proteins needed by bacteria for growth and survival, thus curbing bacterial spread. Rifaximin is administered orally, typically 2 to 3 times daily, depending on the condition being treated. Common side effects may include swelling, dizziness, and fatigue. It's important to note that this antibiotic targets bacterial infections only and is ineffective against viral infections such as the common cold or flu. Always consult with a healthcare professional before starting any medication regimen.
Price history for Xifaxan
42 Tablets, 550MG
Average retail price for Xifaxan
Average SaveHealth price for Xifaxan
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Xifaxan dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 200MG | 9 Tablets | $141.49 | $15.72 |
| 200MG | 30 Tablets | $452.96 | $15.10 |
| 550MG | 42 Tablets | $3,195.61 | $76.09 |
| 550MG | 6 Tablets | $460.80 | $76.80 |
| 550MG | 9 Tablets | $688.70 | $76.52 |
| 550MG | 60 Tablets | $4,563.01 | $76.05 |
| 550MG | 360 Tablets | $27,353.08 | $75.98 |
Xifaxan FAQs
Xifaxan is used to treat certain types of bacterial infections in the intestines. It is commonly prescribed for travelers' diarrhea caused by non-invasive strains of Escherichia coli and for reducing the risk of overt hepatic encephalopathy recurrence in adults. Additionally, it is used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.
Xifaxan is expensive due to several factors, including the cost of research and development, the complexity of manufacturing the drug, and the lack of generic alternatives. Additionally, the pricing strategy of the pharmaceutical company and the drug's effectiveness in treating specific conditions can also contribute to its high cost.
Xifaxan is approved for the treatment of travelers' diarrhea caused by non-invasive strains of Escherichia coli in adults and children aged 12 years and older. It is also approved for reducing the risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Xifaxan (rifaximin) can cause changes in bowel habits, but it does not typically cause an increase in the frequency of bowel movements for most people. It is often used to treat conditions like irritable bowel syndrome with diarrhea (IBS-D) and travelers' diarrhea, where it may help reduce diarrhea. However, individual responses can vary, and some people might experience gastrointestinal side effects. If there are concerns about side effects, it is advisable to consult a healthcare provider.
Insurance coverage for medications like Xifaxan can vary based on several factors, including the specific insurance plan, the formulary list, and the medical necessity as determined by the insurance provider. Xifaxan may not be covered if it is not included in the plan's formulary, if there are less expensive alternatives available, or if the insurance company requires prior authorization and it has not been obtained. Patients are encouraged to contact their insurance provider for specific details regarding coverage and to discuss potential options with their healthcare provider.